What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
about
Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial CellsVascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDCurrent intravitreal pharmacologic therapies for diabetic macular edema.Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child.Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?Introduction. Treatment paradigms within the use of anti-VEGF agents.Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
P2860
Q28066675-EFE45387-C710-4D17-B007-15BEF9DF83C0Q28550616-1F3848D6-4C66-4118-9876-261449B7FD4CQ30244247-E2C20244-51B1-4712-A6AD-B00BF526FB00Q30490738-32AF599F-74D2-41D3-8E43-FC5EDB710200Q34092454-5A6B43B8-1992-4755-AF3C-22DFE3ABB103Q34473329-1030BE01-46B1-4117-8F7E-E362208A22FCQ34608306-B81E174F-E690-4C7B-8717-68BE26399485Q35650268-48D6F0B5-6155-45DB-AC20-C4CDAE99D57FQ36338786-1DF68361-F3FA-41BE-A8FE-05135F0E2BE4Q36752299-A02522B1-FC3C-4A5C-8671-B39C7D9C72C3Q36757415-DCF56D83-E6C7-442F-86D2-874E78C68865Q40990867-DD03F6DE-140C-4434-B799-DA1B5E2D4A3FQ42588556-C1765500-F912-4521-88FF-762A48C3CF07Q48276388-C837A69A-42A2-4279-8F76-C329E145938B
P2860
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
What is the evidence for syste ...... s, and should we be concerned?
@en
type
label
What is the evidence for syste ...... s, and should we be concerned?
@en
prefLabel
What is the evidence for syste ...... s, and should we be concerned?
@en
P2860
P1476
What is the evidence for syste ...... s, and should we be concerned?
@en
P2093
Robert L Avery
P2860
P356
10.1136/BJOPHTHALMOL-2013-303844
P407
P478
98 Suppl 1
P5008
P577
2013-12-10T00:00:00Z
2014-06-01T00:00:00Z